Innoviva, Inc. (INVA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Innoviva, Inc. (INVA) Healthcare & Pipeline Overview

Innoviva, Inc. is a biotechnology company specializing in respiratory disease treatments, marketing partnered products like RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. Through its collaboration with Glaxo Group Limited, Innoviva focuses on commercializing therapies for COPD and asthma, leveraging strategic partnerships to drive revenue and market presence.

What Is the Investment Thesis for INVA?

Innoviva, Inc. presents an intriguing investment case centered on its established portfolio of respiratory drugs and its strategic partnership with Glaxo Group Limited. With a P/E ratio of 3.1 and a profit margin of 65.4%, Innoviva demonstrates strong profitability. The company's revenue is primarily driven by royalties from partnered products like RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. Growth catalysts include continued market penetration of TRELEGY ELLIPTA and potential label expansions for existing products. However, investors may want to evaluate the risks associated with reliance on a single major partnership and the competitive landscape in the respiratory market. The company's low beta of 0.40 suggests relatively low volatility compared to the broader market.

Based on FMP financials and quantitative analysis

INVA Key Highlights

• Market capitalization of $1.56B, reflecting substantial investor valuation.
• P/E ratio of 3.1, indicating potential undervaluation compared to industry peers.
• Profit margin of 65.4%, showcasing efficient operations and strong profitability.
• Gross margin of 78.9%, highlighting effective cost management in pharmaceutical sales.
• Beta of 0.40, suggesting lower volatility compared to the overall market, potentially offering stability to investors.

Who Are INVA's Competitors?

INVA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INVA's Key Strengths?

• Established partnership with Glaxo Group Limited.
• Portfolio of approved respiratory medications.
• High profit margin of 65.4%.
• Strong gross margin of 78.9%.

What Are INVA's Weaknesses?

• Reliance on a single major partnership.
• Limited product diversification.
• Exposure to regulatory and pricing pressures.
• Small number of employees.

What Could Drive INVA Stock Higher?

• Continued market penetration of TRELEGY ELLIPTA.
• Potential label expansions for existing products.
• Regulatory approvals in new geographic markets.
• Strategic partnership with Sarissa Capital Management LP.

What Are the Key Risks for INVA?

• Reliance on a single major partnership with Glaxo Group Limited.
• Competition from generic alternatives.
• Patent expirations on key products.
• Changes in healthcare regulations and reimbursement policies.
• Economic downturn affecting pharmaceutical sales.

What Are the Growth Opportunities for INVA?

• Expansion of TRELEGY ELLIPTA Market Share: TRELEGY ELLIPTA, a triple combination therapy for COPD and asthma, represents a significant growth opportunity for Innoviva. As of 2026, the global market for COPD and asthma treatments is projected to reach $45 billion. By increasing market penetration and securing additional regulatory approvals for broader patient populations, Innoviva can drive revenue growth. The company's established partnership with Glaxo Group Limited provides a strong platform for commercial success and market access.
• Geographic Expansion into Emerging Markets: Innoviva has the opportunity to expand its geographic footprint by entering emerging markets with high unmet needs for respiratory therapies. These markets, particularly in Asia and Latin America, are experiencing rapid growth in COPD and asthma prevalence due to increasing urbanization and pollution. By leveraging its partnership with Glaxo Group Limited, Innoviva can navigate regulatory hurdles and establish distribution networks to capitalize on these emerging market opportunities. This expansion could add significant revenue streams over the next 3-5 years.
• Development of Next-Generation Respiratory Therapies: Innoviva can invest in the research and development of next-generation respiratory therapies, such as inhaled biologics and precision medicine approaches. The market for advanced respiratory treatments is expected to grow significantly as personalized medicine gains traction. By focusing on innovative therapies that address unmet needs and improve patient outcomes, Innoviva can differentiate itself from competitors and secure a leading position in the respiratory market. This strategy requires significant R&D investment but offers substantial long-term growth potential.
• Strategic Acquisitions to Diversify Product Portfolio: Innoviva can pursue strategic acquisitions of companies with complementary respiratory products or technologies. This would allow Innoviva to diversify its product portfolio and reduce its reliance on its partnership with Glaxo Group Limited. Potential acquisition targets could include companies developing novel drug delivery systems, digital health solutions for respiratory management, or therapies for related respiratory conditions such as cystic fibrosis. Strategic acquisitions can accelerate growth and enhance Innoviva's competitive position.
• Leveraging Digital Health Solutions for Patient Engagement: Innoviva can integrate digital health solutions into its respiratory care offerings to improve patient engagement and adherence. This includes developing mobile apps, wearable sensors, and telehealth platforms that provide personalized support and monitoring for patients with COPD and asthma. By leveraging digital health technologies, Innoviva can enhance patient outcomes, reduce healthcare costs, and generate valuable data insights. The market for digital health solutions in respiratory care is rapidly expanding, offering significant growth opportunities for Innoviva.

What Opportunities Does INVA Have?

• Expansion into emerging markets.
• Development of next-generation respiratory therapies.
• Strategic acquisitions to diversify product portfolio.
• Leveraging digital health solutions for patient engagement.

What Threats Does INVA Face?

• Competition from generic alternatives.
• Patent expirations on key products.
• Changes in healthcare regulations and reimbursement policies.
• Potential termination of partnership with Glaxo Group Limited.

What Are INVA's Competitive Advantages?

• Established partnership with Glaxo Group Limited.
• Portfolio of approved respiratory medications.
• Strong intellectual property protection for key products.
• Expertise in respiratory drug development and commercialization.

What Does INVA Do?

Innoviva, Inc., originally founded as Theravance, Inc. in 1996 and rebranded in 2016, is a biopharmaceutical company dedicated to the development and commercialization of respiratory medicines. Headquartered in Burlingame, California, Innoviva operates both in the United States and internationally. The company's primary focus is on therapies for chronic obstructive pulmonary disease (COPD) and asthma, developed through a long-standing collaboration agreement with Glaxo Group Limited. Innoviva markets several key products, including RELVAR/BREO ELLIPTA, a combination medicine containing a long-acting beta2 agonist (LABA) and an inhaled corticosteroid (ICS); ANORO ELLIPTA, which combines a long-acting muscarinic antagonist (LAMA) with a LABA; and TRELEGY ELLIPTA, a triple combination therapy consisting of an ICS, LAMA, and LABA. These once-daily medications are designed to improve patient outcomes and quality of life. Innoviva also maintains a strategic partnership with Sarissa Capital Management LP, enhancing its corporate strategy and financial flexibility. The company's evolution reflects a commitment to respiratory health and strategic collaborations to maximize the market reach and impact of its pharmaceutical products.

What Products and Services Does INVA Offer?

• Develops and commercializes pharmaceutical products.
• Focuses on respiratory disease treatments.
• Markets RELVAR/BREO ELLIPTA for asthma and COPD.
• Markets ANORO ELLIPTA for COPD.
• Markets TRELEGY ELLIPTA for asthma and COPD.
• Partners with Glaxo Group Limited for product development and commercialization.
• Engages in strategic partnerships to expand market reach.

How Does INVA Make Money?

• Generates revenue through royalties from partnered products.
• Collaborates with Glaxo Group Limited for development and commercialization.
• Focuses on licensing and partnership agreements.
• Invests in research and development of new therapies.

What Industry Does INVA Operate In?

Innoviva operates within the global respiratory therapeutics market, which is characterized by increasing prevalence of asthma and COPD. The market is driven by aging populations, rising pollution levels, and advancements in drug delivery systems. Innoviva's collaboration with Glaxo Group Limited positions it as a key player in the COPD and asthma treatment landscape. Competitors include companies focusing on novel respiratory therapies and generic alternatives. The industry is subject to stringent regulatory requirements and pricing pressures, influencing market dynamics.

Who Are INVA's Key Customers?

• Patients with chronic obstructive pulmonary disease (COPD).
• Patients with asthma.
• Healthcare providers prescribing respiratory medications.
• Pharmacies dispensing respiratory medications.
• Hospitals and clinics treating respiratory conditions.

Company Profile

Innoviva, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Burlingame, US. The company is led by CEO Pavel Raifeld. INVA has traded publicly since 2004.

F-Score 4/9Financial Health

Innoviva, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.06 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 48%Key Financial Metrics

Return on equity for Innoviva, Inc. stands at 47.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 27.5%, showing how much profit it generates from its asset base. INVA trades at a trailing price-to-earnings ratio of 3.15, below the Healthcare sector average of ~23x. Its free cash flow yield is 11.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 31.1%, the inverse of the P/E and a quick read on earnings relative to price.

INVA Valuation & Market Position

With a $1.56B market cap, Innoviva, Inc. sits in the small-cap segment of the market. Relative to its peer group, INVA's quantitative score of 91/100 is roughly in line with the peer average of 83/100.

FY2026 estForward Outlook

Wall Street analysts project Innoviva, Inc. revenue of about $440.6M for fiscal 2026, with EPS near $3.57. The estimate reflects 3 contributing analysts.

INVA Financials

INVA Latest News

INVA Analyst Consensus

INVA MoonshotScore

INVA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources